1. Cost—Effective Prescribing in Elderly People

   • D. J. Richard Morgan
   • Carol A. Sutters
   • Brian Livesley

   Leading Article 15 November 2012 Pages: 387 - 393

2. Health—Related Quality of Life Assessment and the Pharmaceutical Industry

   • Dennis A. Revicki
   • Margaret Rothman
   • Bryan Luce

   Review Article 15 November 2012 Pages: 394 - 408

3. Pharmacoeconomics of Antibacterial Treatment

   • Peter G. Davey
   • Mo M. Malek
   • Sharon E. Parker

   Review Article 15 November 2012 Pages: 409 - 437

4. Cost—Utility Analysis of Early Thrombolytic Therapy

   • D. Castiel
   • C. Hervé
   • M. Soula

   Original Research Article 15 November 2012 Pages: 438 - 442

5. Imipenem/Cilastatin

   • Paul Benfield
   • Paul Chrisp

   Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 443 - 459

6. β—Blockers vs Calcium Channel Blockers vs ACE Inhibitors

   • Dahlof C
   • Dimenas E
   • J. Boelaert

   Current Comment 15 November 2012 Pages: 460 - 462

7. Should Indirect Costs and Benefits be Included?

   • David A. Henry

   Correspondence 15 November 2012 Pages: 462 - 462